Develops antibody drug candidates for people with obesity, overweight and metabolic disorders, led by nimacimab, which targets a receptor involved in metabolic regulation.
10-K for FY2025, filed Mar 10, 2026
No revenue reported yet.
10-K, filed Mar 23, 2020
10-Q for Q3 FY2026, filed Nov 13, 2026
$69.1KView ↗
8-K, filed Sep 11, 2026
On September 8, 2026, John P. Sharp resigned as Chief Financial Officer and principal financial and accounting officer of the Company…View ↗
8-K, filed Aug 14, 2026
The Transaction Agreement provides that, subject to the terms and conditions set forth therein, including the requisite approval of each of…View ↗
From eye treatments to metabolic disease
The earlier report centered on synthetic cannabinoid derivatives and an ophthalmic treatment for glaucoma and ocular hypertension. The latest report centers on nimacimab for obesity and metabolic disorders and says the ocular program was eliminated.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 10, 2026
Competes with Novo Nordisk, Eli Lilly, Structure Therapeutics, and Viking Therapeutics
10-K for FY2025, filed Mar 10, 2026The development and commercialization of therapies for the treatment of obesity and overweight is highly competitive. Our product…View ↗
Loading...